Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zepbound
Biotech
Amgen’s late-stage obesity trials expected to read out in ‘27
The MariTime program is also expected to include ph. 3 trials in cardiovascular disease, heart failure, kidney disease and obstructive sleep apnea.
Gabrielle Masson
Mar 5, 2025 1:58pm
Lilly's next focus: Testing incretins in neuro, immunology fields
Feb 6, 2025 2:35pm
Obesity biotech Metsera files for a swift IPO
Jan 11, 2025 9:05am
'All hands on deck' at Lilly as peers target obesity market
Aug 8, 2024 1:40pm
Viking to charge quickly into phase 3 with obesity med
Jul 25, 2024 9:19am
The most valuable R&D projects? You guessed it: obesity
Jul 11, 2024 5:00am
